To derive blood pressure, the device measures the time-of-flight between ultrasound echoes reflected from the anterior and ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for ...

Maintenance therapy with subcutaneous infliximab was more effective than placebo regardless of disease location or segment ...

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...

The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.

Repeated insulin shots at the same site can seed amyloid; consider this diagnosis if absorption seems erratic or glucose control worsens with a persistent lump.

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

Roche’s Lunsumio may be the first CD20xCD3 T-cell engager approved by the FDA, but intravenous administration puts the drug at a disadvantage to AbbVie and Genmab’s subcutaneously injected Epkinly.

The subcutaneous tissue, also known as the hypodermis or superficial fascia, is the layer of tissue that underlies the skin. The terms originate from subcutaneous in Latin and hypoderm in Greek, both ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...